Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin-assisted psychotherapy for depression and anxiety in terminal illness
ACTRN12619001225101Phase 2Completed
- Sponsor
- St Vincent's Hospital Melbourne
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in major depressive disorder (MDD) and anxiety disorder comparing Psilocybin first, then open-label psilocybin with Niacin placebo first, then open-label psilocybin (2 arms). Primary endpoints: Hospital Anxiety and Depression Scale, State-Trait Anxiety Inventory and 1 more. Started Jan 2020; status: completed.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)anxiety disorder
Beyond the preview
Go deeper on ACTRN12619001225101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619001225101.